Immunogenicity to biologics: Mechanisms, prediction and reduction

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 5, 2012, Pages 331-344

  Sethu, Swaminathan ^a   Govindappa, Karthik ^a   Alhaidari, Mohammad ^a   Pirmohamed, Munir ^a   Park, Kevin ^a   Sathish, Jean ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antigen processing; Biologics; Complement; Immunogenicity

Indexed keywords

BETA INTERFERON; BLOOD CLOTTING FACTOR 8 ANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; DRUG ANTIBODY; EPITOPE; ERYTHROPOIETIN ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M ANTIBODY; INSULIN ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADAPTIVE IMMUNITY; ADVERSE OUTCOME; ANAPHYLAXIS; ANTIBODY TITER; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; COMPLEMENT ACTIVATION; GENETIC VARIABILITY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY FORMATION; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS; BIOLOGICAL AGENTS; COMPLEMENT SYSTEM PROTEINS; EPITOPES; HLA ANTIGENS; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; T-LYMPHOCYTES;

EID: 84866630453     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0189-7     Document Type: Review

References (179)

1. Aarskog NK, Maroy T, Myhr KM et al (2009) Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol 212:148-150
2. Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(5 Suppl 1):19-22
3. Antonelli G, Dianzani F (1999) Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 10:413-322
4. Armstrong JK, Hempel G, Koling S et al (2007) Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110:103-111 (Pubitemid 46986423)
5. Bachmann MF, Zinkernagel RM (1997) Neutralizing antiviral B cell responses. Annu Rev Immunol 15:235-270 (Pubitemid 27169281)
6. Bachmann MF, Kundig TM, Kalberer CP et al (1994) How many specific B cells are needed to protect against a virus? J Immunol 152:4235-4241 (Pubitemid 24134380)
7. Bajtay Z, Csomor E, Sandor N et al (2006) Expression and role of Fcand complement-receptors on human dendritic cells. Immunol Lett 104:46-52 (Pubitemid 43330708)
8. Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10:219-227 (Pubitemid 46442221)
9. Baker MP, Reynolds HM, Lumicisi B et al (2010) Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1:314-322
10. Balazs M, Martin F, Zhou T et al (2002) Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17:341-352 (Pubitemid 35279554)
11. Barbosa MD, Vielmetter J, Chu S et al (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 118:42-50 (Pubitemid 43012045)
12. Basu A, Yang K, Wang M et al (2006) Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 17:618-630 (Pubitemid 43794371)
13. Batista FD, Harwood NE (2009) The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9:15-27
14. Bellomi F, Scagnolari C, Tomassini V et al (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215:3-8 (Pubitemid 37272189)
15. Bergamaschini L, Santangelo T, Faricciotti A et al (1996) Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes. J Immunol 156:1256-1261 (Pubitemid 26048124)
16. Bertolotto A, Malucchi S, Sala A et al (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153
17. Bertolotto A, Sala A, Malucchi S et al (2004) Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 75:1294-1299 (Pubitemid 39141336)
18. Bindon CI, Hale G, Bruggemann M et al (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168:127-142
19. Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285 (Pubitemid 43736578)
20. Boyer KM, Cherry JD, Noble GR (1977) IgM and IgG antibody responses following immunization of children and adults with influenza A/NJ/76 vaccines. Dev Biol Stand 39:303-308 (Pubitemid 9093027)
21. Braun A, Kwee L, Labow MA et al (1997) Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14:1472-1478 (Pubitemid 27481082)
22. Buck D, Cepok S, Hoffmann S et al (2011) Influence of the HLADRB1genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 68:480-487
23. Cantor JR, Yoo TH, Dixit A et al (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci USA 108:1272-1277
24. Carroll MC (2004) The complement system in B cell regulation. Mol Immunol 41:141-146 (Pubitemid 38668623)
25. Casadevall N, Nataf J, Viron B et al (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475 (Pubitemid 34441737)
26. Chackerian B, Lenz P, Lowy DR et al (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169:6120-6126 (Pubitemid 36903455)
27. Chng HH, Leong KP, Loh KC (1995) Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy 50:984-987 (Pubitemid 26041846)
28. Clarke JB (2010) Mechanisms of adverse drug reactions to biologics. In Uetrecht J (ed) Adverse drug reactions. Springer, Berlin, pp 454-472
29. Conner SD, Schmid SL (2003) Regulated portals of entry into the cell. Nature 422:37-44 (Pubitemid 36323287)
30. Corona T, Leon C, Ostrosky-Zeichner L (1999) Severe anaphylaxis with recombinant interferon beta. Neurology 52:425 (Pubitemid 29059085)
31. De Groot AS, Berzofsky JA (2004) From genome to vaccine-new immunoinformatics tools for vaccine design. Methods 34:425-428 (Pubitemid 39469048)
32. De Groot AS, Martin W (2009) Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 131:189-201
33. De Groot AS, Moise L (2007) Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 10:332-340 (Pubitemid 46800227)
34. De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482-490 (Pubitemid 350087812)
35. De Groot AS, Knopp PM, Martin W (2005) De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol 122:171-194 (Pubitemid 43002219)
36. De Groot AS, Moise L, McMurry JA et al (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112:3303-3311
37. De Smedt T, Pajak B, Muraille E et al (1996) Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184:1413-1424 (Pubitemid 26354697)
38. Depoil D, Weber M, Treanor B et al (2009) Early events of B cell activation by antigen. Sci Signal 2:pt1
39. DiMasi JA, Feldman L, Seckler A et al (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87:272-277
40. El-Manzalawy Y, Honavar V (2010) Recent advances in B-cell epitope prediction methods. Immunome Res 6(Suppl 2):S2
41. El-Manzalawy Y, Dobbs D, Honavar V (2008) Predicting linear B-cell epitopes using string kernels. J Mol Recognit 21:243-255 (Pubitemid 352019054)
42. Ettinger RA, James EA, Kwok WW et al (2010) HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia 16:44-55
43. Fehr T, Bachmann MF, Bucher E et al (1997) Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185:1785-1792 (Pubitemid 27242200)
44. Fehr T, Naim HY, Bachmann MF et al (1998) T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nat Med 4:945-948 (Pubitemid 28364035)
45. Finkelman FD (2007) Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 120:506-515 (Pubitemid 47334841)
46. Fischer WH, Hugli TE (1997) Regulation of B cell functions by C3a and C3a (desArg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol 159:4279-4286 (Pubitemid 127470584)
47. Fleming SD, Shea-Donohue T, Guthridge JM et al (2002) Mice deficient in complement receptors 1 and 2 lack a tissue injuryinducing subset of the natural antibody repertoire. J Immunol 169:2126-2133 (Pubitemid 34857679)
48. Ganson NJ, Kelly SJ, Scarlett E et al (2006) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8:R12
49. Giezen TJ, Mantel-Teeuwisse AK, Straus SM et al (2008) Safetyrelated regulatory actions for biologicals approved in the United States and the European Union. JAMA 300:1887-1896
50. Goins CL, Chappell CP, Shashidharamurthy R et al (2010) Immune complex-mediated enhancement of secondary antibody responses. J Immunol 184:6293-6298
51. Goodnow CC (2001) Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 357:2115-2121 (Pubitemid 32607460)
52. Greenspan NS, Cooper LJ (1992) Intermolecular cooperativity: a clue to why mice have IgG3? Immunol Today 13:164-168
53. Guy B (2010) Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective. J Comp Pathol 142(Suppl 1):S133-S137
54. Hashimoto M, Hirota K, Yoshitomi H et al (2010) Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med 207:1135-1143
55. Hay CR, Ollier W, Pepper L et al (1997) HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A UKHCDO Inhibitor Working Party. Thromb Haemost 77:234-237 (Pubitemid 27084906)
56. Hay C, Recht M, Carcao M et al (2006a) Current and future approaches to inhibitor management and aversion. Semin Thromb Hemost 32(Suppl 2):15-21
57. Hay CR, Brown S, Collins PW et al (2006b) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 133:591-605 (Pubitemid 43742773)
58. Hayashi F, Smith KD, Ozinsky A et al (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103 (Pubitemid 32391041)
59. Hegen H, Schleiser M, Gneiss C et al (2012) Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 18:610-615
60. Hermeling S, Crommelin DJ, Schellekens H et al (2004) Structureimmunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903
61. Hirsch IB (2005) Insulin analogues. N Engl J Med 352:174-183 (Pubitemid 40096614)
62. Hobeika AC, Morse MA, Osada T et al (2005) Enumerating antigenspecific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 28:63-72 (Pubitemid 40075939)
63. Hochuli E (1997) Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17(Suppl 1):S15-S21 (Pubitemid 27327279)
64. *0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83:219-227
65. Inaba H, Martin W, De Groot AS et al (2006) Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J Clin Endocrinol Metab 91:2286-2294 (Pubitemid 43855019)
66. Jaber A, Baker M (2007) Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 43:1256-1261
67. Jaber A, Driebergen R, Giovannoni G et al (2007) The Rebif new formulation story: it's not trials and error. Drugs R D 8:335-348 (Pubitemid 350014786)
68. Janson ET, Ronnblom L, Ahlstrom H et al (1992) Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3:635-638
69. Jefferis R (2007) Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7:1401-1413 (Pubitemid 47475656)
70. Jevsevar S, Kunstelj M, Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5:113-128
71. Jones TD, Phillips WJ, Smith BJ et al (2005) Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 3:991-1000 (Pubitemid 41632831)
72. Jones JC, Settles EW, Brandt CR et al (2011) Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine 29:7696-7703
73. Kamate C, Lenting PJ, van den Berg HM et al (2007) Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. J Thromb Haemost 5:611-613 (Pubitemid 46680700)
74. Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7:9-18 (Pubitemid 46020823)
75. Kerekes K, Cooper PD, Prechl J et al (2001) Adjuvant effect of gamma-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J Leukoc Biol 69:69-74 (Pubitemid 32095119)
76. Khan AM, Miotto O, Heiny AT et al (2006) A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol 244:141-147 (Pubitemid 46733910)
77. Kivisakk P, Alm GV, Fredrikson S et al (2000) Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 7:27-34 (Pubitemid 32268733)
78. Kopf M, Abel B, Gallimore A et al (2002) Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8:373-378 (Pubitemid 34407032)
79. Koren E, De Groot AS, Jawa V et al (2007) Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124:26-32 (Pubitemid 46938690)
80. Kromminga A, Schellekens H (2005) Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci 1050:257-265 (Pubitemid 41129443)
81. Kulkarni-Kale U, Bhosle S, Kolaskar AS (2005) CEP: a conformational epitope prediction server. Nucleic Acids Res 33(Web Server issue):W168-171 (Pubitemid 44529902)
82. Kumar D (1997) Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 20:1357-1359 (Pubitemid 27366806)
83. Kumar S, Singh SK, Wang X et al (2011) Coupling of aggregation and immunogenicity in biotherapeutics: T-and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res 28:949-961
84. L Revers EF (2010) An introduction to biologics and biosimilars. Part I: Biologics: what are they and where do they come from? Can Pharmacists J 143:134-139
85. Lafuente EM, Reche PA (2009) Prediction of MHC-peptide binding: a systematic and comprehensive overview. Curr Pharm Des 15:3209-3220
86. Lalli PN, Strainic MG, Yang M et al (2008) Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759-1766
87. Lankar D, Vincent-Schneider H, Briken V et al (2002) Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation. J Exp Med 195:461-472 (Pubitemid 34461299)
88. Lanzavecchia A (1990) Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 8:773-793 (Pubitemid 20135646)
89. Larsen JE, Lund O, Nielsen M (2006) Improved method for predicting linear B-cell epitopes. Immunome Res 2:2
90. Lazarski CA, Chaves FA, Jenks SA et al (2005) The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity 23:29-40 (Pubitemid 41019655)
91. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7:21-39
92. Li J, Yang C, Xia Y et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248
93. Li K, Anderson KJ, Peng Q et al (2008) Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood 112:5084-5094
94. Martin F, Oliver AM, Kearney JF (2001) Marginal zone and B1 B cells unite in the early response against T-independent bloodborne particulate antigens. Immunity 14:617-629 (Pubitemid 32520872)
95. McMurry J, Sbai H, Gennaro ML et al (2005) Analyzing Mycobacterium tuberculosis roteomes for candidate vaccine epitopes. Tuberculosis 85:95-105 (Pubitemid 40431321)
96. McMurry JA, Gregory SH, Moise L et al (2007) Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 25:3179-3191 (Pubitemid 46482760)
97. Medzhitov R, Janeway CA Jr (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296:298-300 (Pubitemid 34303673)
98. Meritet JF, Maury C, Tovey MG (2001a) Effect of oromucosal administration of IFN-alpha on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen. J Interferon Cytokine Res 21:583-593 (Pubitemid 32911664)
99. Meritet JF, Maury C, Tovey MG (2001b) Induction of tolerance to recombinant therapeutic proteins. J Interferon Cytokine Res 21:1031-1038 (Pubitemid 34114281)
100. Minuk GY, Hoofnagle JH, McAuliffe VJ et al (1983) IgM antibody responses to hepatitis B surface antigen in recipients of hepatitis B virus vaccine. J Infect Dis 148:330 (Pubitemid 13002469)
101. Mohanan D, Slutter B, Henriksen-Lacey M et al (2010) Administration routes affect the quality of immune responses: a crosssectional evaluation of particulate antigen-delivery systems. J Control Release 147:342-349
102. Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691-697 (Pubitemid 10024715)
103. Mueller R, Karle A, Vogt A et al (2009) Evaluation of the immunostimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci 98:3548-3561
104. Nagler-Anderson C, Terhoust C, Bhan AK et al (2001) Mucosal antigen presentation and the control of tolerance and immunity. Trends Immunol 22:120-122 (Pubitemid 32675252)
105. O'Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10:801-805 (Pubitemid 39070850)
106. Ohta H, Takahashi I, Kojima T et al (1999) Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies. Tissue Antigens 54:91-97 (Pubitemid 29326935)
107. Ottonello L, Corcione A, Tortolina G et al (1999) rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. J Immunol 162:6510-6517 (Pubitemid 29309373)
108. Parker AS, Griswold KE, Bailey-Kellogg C (2011) Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. J Bioinform Comput Biol 9:207-229
109. Pedotti R, Mitchell D, Wedemeyer J et al (2001) An unexpected version of horror autotoxicus: anaphylactic shock to a selfpeptide. Nat Immunol 2:216-222 (Pubitemid 33705997)
110. Peng A, Gaitonde P, Kosloski MP et al (2009) Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci 98:4480-4484
111. Pereira LF, de Souza AP, Borges TJ et al (2011) Impaired in vivo CD4+ T cell expansion and differentiation in aged mice is not solely due to T cell defects: decreased stimulation by aged dendritic cells. Mech Ageing Dev 132:187-194
112. Perini P, Facchinetti A, Bulian P et al (2001) Interferon-beta (INFbeta) antibodies in interferon-beta1a-and interferon-beta1btreated multiple sclerosis patients. Prevalence, kinetics, crossreactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12:56-61 (Pubitemid 32281190)
113. Pichler WJ (2006) Adverse side-effects to biological agents. Allergy 61:912-920 (Pubitemid 44024887)
114. Ponce R, Abad L, Amaravadi L et al (2009) Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54:164-182
115. *0309. Nephrol Dial Transplant 24:1545-1549
116. Price KS, Hamilton RG (2007) Anaphylactoid reactions in two patients after omalizumab administration after successful longterm therapy. Allergy Asthma Proc 28:313-319
117. Pungor E Jr, Files JG, Gabe JD et al (1998) A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 18:1025-1030 (Pubitemid 29011609)
118. Purcell RT, Lockey RF (2008) Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 18:335-342
119. Rader RA (2008) (Re) defining biopharmaceutical. Nat Biotechnol 26:743-751
120. Radstake TR, Svenson M, Eijsbouts AM et al (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68:1739-1745
121. Rafi A, Castle SC, Uyemura K et al (2003) Immune dysfunction in the elderly and its reversal by antihistamines. Biomed Pharmacother 57:246-250 (Pubitemid 36897691)
122. Reding MT (2006) Immunological aspects of inhibitor development. Haemophilia 12(Suppl 6):30-35; discussion 35-36
123. Reding MT, Lei S, Lei H et al (2002) Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 88:568-575 (Pubitemid 35173996)
124. Regnault A, Lankar D, Lacabanne V et al (1999) Fcgamma receptormediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189:371-380 (Pubitemid 29063258)
125. Reid RR, Woodcock S, Shimabukuro-Vornhagen A et al (2002) Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol 169:5433-5440 (Pubitemid 35291640)
126. Reijonen H, Novak EJ, Kochik S et al (2002) Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 51:1375-1382 (Pubitemid 34826602)
127. Rice GP, Paszner B, Oger J et al (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52:1277-1279 (Pubitemid 29177937)
128. Richard J, Prang N (2010) The formulation and immunogenicity of therapeutic proteins: product quality as a key factor. Drugs 13:550-558
129. Richter AW, Akerblom E (1984) Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 74:36-39 (Pubitemid 14136479)
130. Robbins DC, Cooper SM, Fineberg SE et al (1987) Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36:838-841 (Pubitemid 17145305)
131. Ronnblom LE, Janson ET, Perers A et al (1992) Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 89:330-335
132. Rosenberg AS (2003) Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol 112:15-21
133. Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:E501-E507 (Pubitemid 44294011)
134. Ross C, Clemmesen KM, Svenson M et al (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48:706-712
135. Rutault K, Alderman C, Chain BM et al (1999) Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic Biol Med 26:232-238
136. Rychly DJ, DiPiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25:1181-1192 (Pubitemid 41242578)
137. Saha S, Bhasin M, Raghava GP (2005) Bcipep: a database of B-cell epitopes. BMC Genomics 6:79
138. Scagnolari C, Bellomi F, Turriziani O et al (2002) Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsingremitting multiple sclerosis patients treated with different IFNbeta preparations. J Interferon Cytokine Res 22:207-213 (Pubitemid 34275488)
139. Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457-462 (Pubitemid 37361488)
140. Schellekens H (2003) Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 18:1257-1259 (Pubitemid 36826943)
141. Schellekens H (2008) Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 21:497-502
142. Scherer K, Spoerl D, Bircher AJ (2010) Adverse drug reactions to biologics. J Dtsch Dermatol Ges 8:411-426
143. Schreiber A, Humbert M, Benz A et al (2005) 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J Comput Chem 26:879-887 (Pubitemid 40860391)
144. Shopnick RI, Kazemi M, Brettler DB et al (1996) Anaphylaxis after treatment with recombinant factor VIII. Transfusion 36:358-361 (Pubitemid 26141065)
145. Shurin MR, Shurin GV, Chatta GS (2007) Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol 64:90-105 (Pubitemid 47488893)
146. Simonney N, De Bosch N, Argueyo A et al (1985) HLA antigens in hemophiliacs A with or without factor VIII antibodies in a Venezuelan Mestizo population. Tissue Antigens 25:216-219 (Pubitemid 15032983)
147. Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354-387
148. Sollner J, Grohmann R, Rapberger R et al (2008) Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins. Immunome Res 4:1
149. Sorensen PS, Ross C, Clemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191 (Pubitemid 37255344)
150. Sparwasser T, Koch ES, Vabulas RM et al (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28:2045-2054 (Pubitemid 28271721)
151. Steele RH, Limaye S, Cleland B et al (2005) Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology 10:317-320 (Pubitemid 40910382)
152. Steere AC, Klitz W, Drouin EE et al (2006) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 203:961-971
153. Steis RG, Smith JW 2nd, Urba WJ et al (1991) Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood 77:792-798
154. Stickler M, Valdes AM, Gebel W et al (2004) The HLA-DR2haplotype is associated with an increased proliferative response to the immunodominant CD4 (+) T-cell epitope in human interferon-beta. Genes Immun 5:1-7 (Pubitemid 38967623)
155. Strainic MG, Liu J, Huang D et al (2008) Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28:425-435
156. Stubenrauch K, Wessels U, Birnboeck H et al (2010) Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 32:1597-1609
157. Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028 (Pubitemid 44343545)
158. Svenson M, Geborek P, Saxne T et al (2007) Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 46:1828-1834 (Pubitemid 350168300)
159. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507-519
160. Tangri S, Mothe BR, Eisenbraun J et al (2005) Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 174:3187-3196 (Pubitemid 40354020)
161. van Beers MM, Jiskoot W, Schellekens H (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res 30:767-775
162. van Beers MM, Sauerborn M, Gilli F et al (2011) Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28:2393-2402
163. van Haren SD, Herczenik E, ten Brinke A et al (2011) HLA-DRpresented peptide repertoires derived from human monocytederived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics 10:M110.002246
164. von Delwig A, Altmann DM, Isaacs JD et al (2006) The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum 54:482-491 (Pubitemid 43228622)
165. von Wussow P, Jakschies D, Freund M et al (1989) Humoral response to
166. Vos Q, Lees A, Wu ZQ et al (2000) B-cell activation by T-cellindependent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176:154-170
167. Vultaggio A, Matucci A, Nencini F et al (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65:657-661
168. Vultaggio A, Maggi E, Matucci A (2011) Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 11:262-268
169. Wadhwa M, Meager A, Dilger P et al (2000) Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology 99:113-123 (Pubitemid 30062946)
170. Wang W (2005) Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30 (Pubitemid 40093537)
171. Wang Y, Wu W, Negre NN et al (2011) Determinants of antigenicity and specificity in immune response for protein sequences. BMC Bioinformatics 12:251
172. Warrier I, Ewenstein BM, Koerper MA et al (1997) Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 19:23-27 (Pubitemid 27124054)
173. Weaver DJ Jr, Reis ES, Pandey MK et al (2010) C5a receptordeficient dendritic cells promote induction of Treg and Th17cells. Eur J Immunol 40:710-721
174. Weber RW (2004) Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunol 4:277-283 (Pubitemid 39006842)
175. Weber G, Gross J, Kromminga A et al (2002) Allergic skin and systemic reactions in a patient with pure red cell aplasia and antierythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 13:2381-2383 (Pubitemid 34925249)
176. Woof JM, Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4:89-99 (Pubitemid 38209203)
177. Yeung VP, Chang J, Miller J et al (2004) Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172:6658-6665 (Pubitemid 38669101)
178. Zhao L, Wong L, Li J (2011) Antibody-specified b-cell epitope prediction in line with the principle of context-awareness. IEEE/ACM Trans Comput Biol Bioinform 8:1483-1494
179. Zhou W, Patel H, Li K et al (2006) Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 107:2461-2469 (Pubitemid 43345568)